ArticleVirulence2025
Culture breakthrough enables goose circovirus (GoCV) isolation and pathogenic gosling modeling to uncover the association between viral infection and vaccine failure.
Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunoevaluation of a Prokaryotic-Expressed Goose Circovirus Capsid Subunit Vaccine.Microorganisms · 2026Article
- Overview of waterfowl circovirus: research progress and future perspectives.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Goose circovirus (GoCV), recognized as the most economically significant immunosuppressive pathogen in global waterfowl production, causes considerable economic losses annually, and multiprovincial surveillance studies have documented high seroprevalence rates. The critical barrier to combating GoCV has persisted in the complete absence of viable in vitro culture systems, fundamentally limiting pathogenesis studies and vaccine development. In a breakthrough advancement, this study pioneers the first successful establishment of a stable primary goose embryo kidney (GEK) cell culture system for GoCV propagation, achieving sustained viral replication through innovative culture protocol optimization. Comprehensive virological characterization via synchronized growth curve analysis, transmission electron microscopy, and IFA quantification not only confirms efficient viral proliferation but also resolves longstanding debates regarding the intracellular replication mechanisms of GoCV, termed GoCV/369/2020. Pathogenesis trials involving gosling with the novel isolated GoCV revealed unprecedented clinicopathological correlations, revealing severe growth retardation, feather disorders, persistent fecal shedding, and biphasic organ damage progression from acute hypertrophy to chronic atrophy. Most critically, we provide the first experimental evidence linking GoCV infection to catastrophic vaccine failure, showing reductions in the antibody titers of avian influenza virus and Newcastle disease virus. This breakthrough has led to the establishment of poultry industry solutions, such as standardized viral isolation for diagnostics, optimized vaccination schedules, and targeted biosecurity against fecal-oral transmission. This study established a stable in vitro culture system and a pathogenic gosling model for GoCV, elucidating its replication, pathogenesis, and vaccine interference, providing crucial insights for future research and control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.